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ABSTRACT
Breast cancer is a major malignancy among Indonesian women. It is often diagnosed in 
the later stages of cancer, which leads to poor prognosis and survival of the patients. 
This study investigated plasma DNA concentration as a potential biomarker for breast 
cancer. The benefit of using this detection is the cost-effectiveness and the samples can 
be collected from patients using non-invasive methods. Plasma samples were obtained 
from healthy controls (n=18) and cancer patients (n=22). Each sample was split into 
two equal portions for DNA isolation using two different methods for the NaI method 
and a commercially available kit (Qiagen/ QA) method. The DNA concentration was 
determined by using a GeneQuant spectrophotometer (Pharmacia). The t-test was used 
for statistical analysis, which was performed using the SPSS 17.0 software. Compared to 
the commercial method, extraction using NaI yielded higher DNA concentration, both from 
samples of healthy controls and cancer patients (p=0,008 and p=0.000, respectively). 
Furthermore, regardless of the isolation method used, the plasma DNA concentration 
was higher in healthy controls than in cancer cases (p=0,032 and p=0.005, for NaI 
and QA methods, respectively). In conclusion, isolation methods significantly affect DNA 
concentrations. The plasma DNA concentration of healthy controls is significantly higher 
than those of the cancer cases, suggesting that plasma DNA concentration might be a 
potential biomarker for breast cancer detection with less invasive sampling method than 
tissue biopsies. 
ABSTRAK
Kanker payudara adalah keganasan utama pada wanita di Indonesia. Penyakit ini seringkali 
terdiagnosis pada stadium lanjut sehingga mengakibatkan rendahnya keberhasilan 
pengobatan dan ketahanan hidup pasien yang buruk. Studi ini meneliti potensi DNA plasma 
sebagai penanda biologis untuk mendeteksi kanker payudara. Penggunaan DNA plasma 
sebagai penanda biologis dianggap menguntungkan mengingat analisisnya yang ekonomis 
dan menggunakan pendekatan yang tidak invasif. Sampel plasma darah diperoleh dari 
individu sehat (n=18) dan pasien kanker payudara (n=22) setelah mendapat persetujuan 
dengan menandatangani informed-consent. Setiap sampel dipisahkan menjadi 2 bagian 
dengan volume yang sama untuk diekstrasi menggunakan 2 metode yang berbeda yaitu 
metode Na-I dan kit ekstraksi komersial (Qiagen/QA). Konsentrasi DNA plasma diukur 
dengan spektrofotometer (Genequant, Pharmacia). Analisis statistik t-tes digunakan untuk 
melihat perbedaan kedua metode tesebut. Metode ekstraksi Na-I menujukkan konsentrasi 
DNA yang lebih tinggi dibandingkan kit komersial, baik pada individu sehat (p=0.008) 
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maupun pasien kanker payudara (p=0.000). Sejalan dengan hasil di atas, konsentrasi DNA 
plasma pada individu sehat lebih tinggi daripada penderita kanker payudara menggunakan 
2 metode yang berbeda (NaI p=0.032 dan kit komersial p=0.005). Dapat disimpulkan 
bahwa metode ekstraksi DNA menentukan konsentrasi DNA yang diperoleh. Terdapat 
perbedaan bermakna antara konsentrasi DNA individu sehat dan penderita kanker 
payudara. Hal ini semakin memperkuat potensi DNA plasma sebagai penanda biologis 
untuk deteksi kanker payudara yang kurang invasif dibandingkan biopsi jaringan. 
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INTRODUCTION
Breast cancer is a major malignancy among 
women in Indonesia and rest of the world. 
The incidence of breast cancer is increasing 
in developing countries, and the majority of 
the cases are diagnosed at an advanced stage, 
leading to poor therapeutic outcomes.1 Early 
and accurate diagnosis of breast cancer can 
increase therapeutic efficacy.2 Therefore, 
early detection of circulating analytes may 
help clinicians in providing optimal therapy. 
Plasma DNA can be detected in the blood 
circulation. Several studies have reported that 
plasma DNA of cancer patients present genetic 
and epigenetic changes that are specific to the 
type of cancer, indicating that this DNA is 
tumor-derived. Although the precise source 
of this DNA is still being investigated, it 
is expected to come from a combination 
of apoptosis, necrosis, and release by the 
tumor cells.3 Quantitative changes in plasma 
DNA has been observed in several cancers, 
including the prostate cancer,4,5 lung cancer,6 
pancreatic cancer,7 colon cancer,8,9 ovarian 
cancer,10 and breast cancer.11 High plasma 
DNA concentration has been correlated with 
tumor metastasis,12 response to therapy, 
and relapse.13 This suggests that the plasma 
DNA has the potential to be a tumor-specific 
biomarker for diagnosis, prognosis, and early 
detection of cancer.
Methods of plasma DNA isolation range 
from using a simple manual method to 
using the different kits produced by various 
manufacturers that offer convenience and 
more efficient time. However, these methods 
differ in their efficiency. Therefore, in this 
study we analyzed the performance of a 
simple manual method of extraction and 
compared it effectiveness, efficiency, and 
cost-effectiveness to that of a commercially 
available method in the isolation and 
quantification of plasma DNA. This study 
is important to find a possible alternative 
biomarker for early detection of cancer 
diagnosis, prognosis, and therapy monitoring 
compared to the invasive methods, such as 
tissue biopsy. Furthermore, the findings of this 
study can be used to identify the difference of 
plasma DNA concentration between healthy 
controls and cancer cases. 
MATERIALS AND METHODS
Study participants
Healthy participants were recruited from 
the local Red Cross chapter. The inclusion 
criteria were as follows: female aged 25 
to 35 years, healthy (no history of chronic 
diseases, such as diabetes mellitus type 2 
and/or cardiovascular disease), and a willing 
to participate in the study by signing the 
informed consent. The cancer cases were 
comprised of breast cancer patients admitted to 
the Dr. Sardjito General Hospital, Yogyakarta 
between the years 2009 and 2010. The Ethical 
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Clearance, number KE/FK/625/EC, issued 
by the Health and Medical Research Ethics 
Committee of the Faculty of Medicine, 
Universitas Gadjah Mada, Yogyakarta), 
stated that this research meets all ethical 
requirements. Written informed consent was 
obtained from all participants included in this 
study.
Plasma DNA Isolation
Ten mL of blood samples were withdrawn 
from study participants by using a vacutainer 
with EDTA. Plasma samples were isolated 
by centrifuging the vacutainer at 1200 g 
for10 minutes. Each sample collected from 
the controls and patients were divided into 
two equal portions for extracting DNA 
using two different methods, namely the NaI 
method and the extraction method using a 
commercially available kit (QiaAmp DNA 
mini kit, cat #51104). The NaI method, 
which was developed by Ishizawa et al. in 
1991,14 involved solubilization of proteins 
with a high concentration of  NaI (chaotropic 
reagent) and N-lauryl-sarcosinate, followed 
by the precipitation of the nucleic acids with 
isopropanol.
Plasma DNA Quantification
The plasma DNA isolated was quantified 
by using a Gene Quantspectrophotometer 
(Pharmacia), and the residual samples were 
stored at 4°C.
Statistical Analysis
Data analysis was performed by using 
the SPSS 17.0 software. The Student’s t-test 
was used to find the significant differences 
between the plasma DNA concentrations 
obtained using the two isolation methods and 
to find the significant differences between the 
plasma DNA concentrations of the controls 
and the cancer patients. For identifying the 
significant differences between the plasma 
DNA concentrations from two isolation 
methods, a t-test with equal variance was used, 
whereas a t-test with unequal variance was 
used for identifying the significant differences 
between the plasma DNA concentrations of 
controls and patients. 
RESULTS
The previous reports on the source and 
mechanisms of the sourcing of plasma DNA 
into the circulation is often contradictory. 
Nevertheless, it is thought that originated 
from different sources, including the apoptotic 
and necrotic cells.3 It has been suggested that 
all living cells actively release DNA into the 
circulation.15 There are many DNA extraction 
kits available currently that offer high 
efficiency fast and easy procedures. However, 
they are costly. Therefore, we compared the 
performance of the standardized protocol 
provided by the commercially available 
extraction kit from Qiagentothat of the manual 
protocol developed by Ishikawa.
The result of this study showed that the 
NaI method is more efficient and cost-effective 
than the commercial kit. The NaI method 
yielded higher plasma DNA concentrations. 
Furthermore, the results showed that 
regardless of the isolation method, the plasma 
DNA concentrations in healthy controls were 
significantly higher than that in the cancer 
cases (TABLE 1 and FIGURE 1). 
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TABLE 1. Comparison of plasma DNA concentrations (ng/mL)
Sample Salting out (NaI) Commercially available kit (QA) p
Healthy controls 69.69 ± 31.83 34.04 ± 15.82 0.008*
Cancer cases 40.64 ± 19.14 14.20 ± 4.22 0.000*
p 0.032# 0.005#
*Statistical analysis was performed using Student’s t-test with equal variance
#Statistical analysis was performed using Student’s t-test with unequal variance
FIGURE 1. Illustration of plasma DNA concentrations
DISCUSSION
As a highly malignant disease that causes 
increased mortality rate among women in 
Indonesia, breast cancer is still a challenge 
due to the poor diagnosis and prognosis of the 
disease that could hinder therapy. The routine 
diagnosis and prognosis of breast cancer 
typically depends on solid tissue as the source 
of analysis. Tissue can be harvested only using 
an invasive surgical methods. It is not always 
possible to surgically harvest patient’s tissue 
for monitoring the disease and outcome of the 
therapy. Therefore, an analyte that circulates 
in the body can be used for non-invasive or 
minimally invasive diagnostic, prognostic, 
and monitoring purposes. Plasma DNA is an 
ideal candidate for these purposes. 
Analysis of plasma DNA is a challenging 
method due to the high degree of DNA 
fragmentation and its low concentration in 
the circulation. An earlier study on the source 
of circulating plasma DNA revealed that 
although the concentration of DNA in the 
serum can be 2 to 24 times higher than that 
in the plasma, plasma is a better source than 
serum for the analysis of circulating DNA.16 
The higher abundance of DNA in the serum 
was attributed to the contamination from 
cells that occur during the clotting process. 
Therefore, many laboratories recommended 
the use of plasma as a source of circulating 
DNA. 
Although the ranges of plasma DNA 
concentrations in healthy individuals and 
cancer patients remain unknown, this study 
showed that regardless of the isolation 
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methods, there is a significant difference 
between the plasma DNA concentrations of 
controls and cancer patients. Further studies 
are needed to fully understand whether the 
plasma DNA concentrations reflected DNA 
in the tissues or the clinical manifestations. 
The non-invasive nature of sample collection 
and the efficient and cost-effective of its 
isolation method enable the use of plasma 
DNA concentration as a potential biomarker 
for breast cancer. This biomarker can be used 
for early diagnosis, prognosis, and therapy 
monitoring purposes. 
Majority of the earlier studies found 
that DNA concentration in the plasma of 
cancer patients is higher compared to healthy 
controls. This finding contradictive with our 
results. The differences in the time elapsed 
between the sample collection and the start of 
the isolation procedure likely the reason for 
this contradiction. The plasma from patients’ 
blood samples were isolated immediately 
after receiving the samples, while the samples 
from healthy controls were isolated 2 to 4 
weeks later. Therefore, the higher abundance 
of plasma DNA in healthy controls was likely 
due to the release of fragmented DNA from 
lysed cell during this elapsed time.
Selection of an isolation method that 
ensures the extraction of a sufficient amount 
of high-quality DNA is critical, and pre-
analytical factors of blood sampling and 
processing can strongly affect DNA yield.17
CONCLUSION
The present study shows that isolation 
methods significantly affected the DNA 
concentrations. Furthermore, there is a 
significant difference between the plasma 
DNA concentrations of healthy controls and 
of cancer cases, suggesting its potential utility 
as a biomarker for breast cancer that the 
sampling method is less invasive than tissue 
biopsies.
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